Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GlaxoSmithKline’s Arzerra Gets Better CLL Label, But Now Faces Competition With Gazyva

This article was originally published in The Pink Sheet Daily

Executive Summary

GlaxoSmithKline exec Klaus Edvardsen says the new label should give drug a boost, as previous indication was very restrictive. Approved in 2009, Arzerra had just £75 million in 2013 worldwide sales.

You may also be interested in...



NICE’s Nod To Arzerra In CLL A Prelude To Rivalry With Gazyvaro, MabThera

The U.K.’s NICE has given the nod to GSK’s Arzerra (ofatumumab) for first-line CLL, making an eventual rivalry with Roche’s Gazyvaro and potentially revived MabThera a possibility.

CLL Market Snapshot: Seismic Changes Rock The Treatment Landscape

The market for chronic lymphocytic leukemia drugs is undergoing big changes, with three new drugs approved: Roche’s antibody Gazyva and two oral therapies from Pharmacyclics/J&J and Gilead. Side effect profiles, administration and progression-free survival rates are helping to guide treatment decisions.

Payers Come To Terms With Long-Term Coverage Of New CLL Drugs

WellPoint’s new oncology treatment pathway for CLL, released in September, will use higher payments to doctors to steer them to drugs it feels offer the best outcomes and value.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS063835

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel